Rise in Futura Medical shares is attributed to receipt of $5 million US milestone payment

2 min read | October 07, 2024 03:23 AM PDT | By Team Kalkine Media

Google News:

Rise in Futura Medical shares is attributed to receipt of $5 million US milestone payment — Image source: Shutterstock

Recent News

Oracle's AI Push Gains Ground Across Critical Services

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Make Kalkine Media
My Trusted Source

Highlights:

Futura Medical PLC secures a significant milestone payment following the US launch of its erectile dysfunction gel, Eroxon.
Eroxon becomes the first over-the-counter treatment for erectile dysfunction available in the US market.
Stifel projects substantial peak sales for Eroxon, indicating considerable potential for Futura Medical.

Futura Medical PLC {OTC:FAMDF} experienced a rise in share price during early trading after the company achieved a milestone payment associated with the recent US launch of its erectile dysfunction gel, Eroxon. This payment was initiated as distribution partner Haleon commenced the fulfillment of online pre-orders and made the product available in various retail stores across the United States.

Eroxon stands out as the first over-the-counter treatment for erectile dysfunction in the US, marking a significant milestone in the availability of non-prescription options for consumers. The anticipation surrounding the product's introduction has created considerable market interest, particularly as it addresses a prevalent health concern in a more accessible manner.

Futura Medical anticipates the receipt of the milestone payment shortly, reflecting confidence in the product's performance in the market. In the initial hour of trading, shares rose slightly to 33.55p, reflecting a positive reception from market participants.

Stifel, a prominent financial services firm, has provided insight into the market potential for Eroxon. The firm estimates that peak sales for the product could reach approximately £176 million, with the US market opportunity valued at around 100p per share. This evaluation highlights the significant commercial prospects for Futura Medical as it continues to navigate the evolving landscape of over-the-counter health solutions.

The outlook for Futura Medical remains optimistic, with analysts noting the company's undervalued position and the substantial upside potential tied to Eroxon. The prospect of generating royalties from US sales is expected to enhance operational leverage, especially given the company’s existing fixed cost base. This strategic positioning suggests that Futura Medical is well-prepared to capitalize on the market's response to Eroxon, further solidifying its role in the sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.